Form 4: VolitionRx Chief Scientific Officer Amends Stock Options

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, amended his stock options, effectively replacing older options with new ones that have a later expiration date.

Summary

• Jacob Vincent Micallef, the Chief Scientific Officer of VolitionRx Ltd, has amended his stock options.
• The amendment involved the cancellation of existing options and the grant of replacement options.
• The original options were granted on February 11, 2019, vested after 12 months, and were exercisable for five years.
• The replacement options are fully vested and expire on February 11, 2029, which is ten years from the original grant date.
• Both the old and new options have an exercise price of $3.25.
• The transaction involved 50,000 options.

Sentiment

Score: 7

Explanation: The document reflects a routine administrative action related to executive compensation, which is generally neutral to positive. The extension of the option period could be seen as a positive for the executive.

Positives

• The extension of the option expiration date may provide the executive with more time to benefit from potential stock price appreciation.
• The replacement options are fully vested, providing immediate access to the potential benefit.

Industry Context

This type of stock option amendment is a common practice in corporate governance to retain key executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants and amendments are standard practice for executive compensation across various industries.
• The vesting and expiration terms are within typical ranges for similar roles in comparable companies.
• Companies like Exact Sciences and Guardant Health also use stock options as part of their executive compensation packages.

Stakeholder Impact

• The stock option amendment may have a minor positive impact on shareholder sentiment due to the alignment of executive interests with long-term company performance.
• The amendment has a positive impact on the executive by extending the potential benefit from the options.

Key Dates

Keywords

stock options, executive compensation, insider trading, VolitionRx, VNRX, Jacob Vincent Micallef, Chief Scientific Officer